Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026

Sensei Biotherapeutics, Inc.

14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).
All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.
Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).
Phase 2 initiation expected Q1 2026, subject to sufficient capital.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-065634
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.135133+00:00
generated_at: 2026-05-24T04:14:26.562375+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-065634
json_url: https://secwatch.observer/filing/0001193125-25-065634.json
markdown_url: https://secwatch.observer/filing/0001193125-25-065634.md
text_url: https://secwatch.observer/filing/0001193125-25-065634.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/0001193125-25-065634-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/d831325d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-065634

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.